Niagen Bioscience (NASDAQ:NAGE) Rating Lowered to Hold at Wall Street Zen
by Doug Wharley · The Cerbat GemNiagen Bioscience (NASDAQ:NAGE – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.
Several other research analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. Canaccord Genuity Group reissued a “buy” rating and set a $13.00 price objective on shares of Niagen Bioscience in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Niagen Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.
Read Our Latest Analysis on Niagen Bioscience
Niagen Bioscience Stock Performance
Shares of Niagen Bioscience stock opened at $4.93 on Friday. The stock has a market capitalization of $394.79 million, a PE ratio of 24.65 and a beta of 2.23. Niagen Bioscience has a 52-week low of $4.16 and a 52-week high of $14.69. The company has a 50-day simple moving average of $4.78 and a two-hundred day simple moving average of $5.95.
Institutional Trading of Niagen Bioscience
Several large investors have recently added to or reduced their stakes in NAGE. Vanguard Group Inc. bought a new stake in Niagen Bioscience during the third quarter valued at approximately $37,522,000. Arrowstreet Capital Limited Partnership bought a new stake in Niagen Bioscience during the third quarter valued at approximately $13,405,000. UBS Group AG bought a new stake in Niagen Bioscience during the third quarter valued at approximately $11,160,000. Qube Research & Technologies Ltd bought a new stake in Niagen Bioscience during the third quarter valued at approximately $8,175,000. Finally, Millennium Management LLC bought a new stake in Niagen Bioscience during the third quarter valued at approximately $7,224,000. 15.41% of the stock is currently owned by institutional investors.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.